Onglyza, the popular name for the oral hypoglycemic drug Saxagliptin, marketed by Bristol-Myers Squibb, has been tied to a number of serious side effects, including anaphylactic shock, acute pancreatitis and upper respiratory tract infection. The drug, marketed for treatment of type 2 diabetes, came under investigation by the FDA in 2014 after reports of higher than normal cardiac mortality rates among users. According to FDA reports, individuals for whom Onglyza had been prescribed had a 27% higher risk of heart failure than those not using the product.
Onglyza has also been tied to increased incidences of pancreatic and thyroid cancer. The FDA has called for warnings to appear on the drug’s label, referring to the cancer and cardiac risks.
Pharmaceutical Litigation Attorneys at Bailey & Galyen have extensive experience in cases involving injury or wrongful death associated with prescription drugs. Contact the attorneys at Bailey & Galyen online or call our office at 844-402-2992 for a free initial consultation.
Our phones are answered 24 hours a day, seven days a week 844-402-2992